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Abstract 
Background: Tumor necrosis factor alpha (TNFα) and interferon gamma (IFNγ) were originally identified to show 
potent anti-tumor activity and immunomodulatory capability. Unfortunately, several clinical studies of relevant cancer 
therapy did not observe significant response in maximum tolerated dose whether given alone or in combination. We 
have identified a tumor vasculature homing peptide (TCP-1 peptide) which targets only the vasculature of colorectal 
tumors but not normal blood vessels in animals and humans. In the current study, the antitumor effect of TCP-1/TNFα 
and TCP-1/IFNγ alone or in combination was studied in orthotopic colorectal tumor model.
Methods: TCP-1/TNFα and TCP-1/IFNγ recombinant proteins were prepared and i.v. injected to study the in vivo anti-
cancer effect in orthotopic colorectal tumor model. Tumor apoptosis was determined by TUNEL staining and cleaved 
caspase-3 immunofluorescent staining. Tumor infiltrating lymphocytes were analyzed by immunofluorescent staining 
and flow cytometry. Western-blot was performed to examine the expression of proteins. Cell apoptosis was measured 
by Annexin V/PI flow cytometry.
Results: Targeted delivery of TNFα or IFNγ by TCP-1 peptide exhibited better antitumor activity than unconjugated 
format by inducing more tumor apoptosis and also enhancing antitumor immunity shown by increased infiltration of 
T lymphocytes inside the tumor. More importantly, combination therapy of TCP-1/TNFα and TCP-1/IFNγ synergistically 
suppressed tumor growth and alleviated systematic toxicity associated with untargeted therapy. This combination 
therapy induced massive apoptosis/secondary necrosis in the tumor.
Conclusions: Taken together, our data demonstrate TCP-1 is an efficient drug carrier for targeted therapy of colorec-
tal cancer (CRC). TCP-1/TNFα combined with TCP-1/IFNγ is a promising combination therapy for CRC.
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Background
Despite a slight decline in the mortality rate over the past 
decade, colorectal cancer (CRC) remains the third most 
common cancer and a leading cause of cancer deaths 
worldwide. Tumor necrosis factor alpha (TNFα) con-
sists of three noncovalently linked TNFα monomers, 
~17.5  kDa each, which forms a compact bell-shaped 
homotrimer [1, 2]. TNFα is a powerful anti-tumor 
cytokine as well as a potent inflammatory cytokine which 
can induce complex immune responses [3]. It exerts its 
anti-tumor activity through complex mechanisms includ-
ing induction of inflammatory and immune responses, 
tumor cell apoptosis/necrosis and extensive thrombosis 
and destruction of tumor vasculature [4, 5]. Although 
TNFα shows potent anti-tumor activity and produces 
impressive results in various animal cancer models, clini-
cal use of TNFα as an anticancer drug is hampered by 
severe systemic toxicity [6, 7]. To date, the clinical use of 
TNFα has been limited to cancer treatment in the iso-
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and melanoma intrinsic metastases confined to the limb 
[8, 9].
It has been shown that tumor vascular-targeted deliv-
ery of TNFα is capable of increasing tumor concentra-
tion of TNFα and directing TNFα specifically to the 
tumor site [6, 10–12]. This strategy has resulted in sev-
eral tumor vascular ligands fused to TNFα for cancer 
therapy research, and even clinical trials are underway 
[13–16]. We have previously established an orthotopic 
colorectal tumor model and identified a cyclic peptide 
known as TCP-1. This peptide can specifically target 
the vasculature of orthotopic colorectal tumors [17]. 
Targeted delivery of TNFα by TCP-1 peptide displayed 
more potent antitumor activity than unconjugated 
TNFα by inducing more apoptosis and destructing neo-
vasculature in orthotopic colorectal tumors at 24 h with 
the dose 5  μg/mouse. Furthermore, low-dose TCP-1/
TNFα (1 ng/mouse) potentiated the antitumor effect of 
5-fluorouracil (5-FU) by normalizing the tumor vascu-
lature, facilitating the infiltration of immune cells to the 
tumor as well as improving 5-FU penetration into the 
tumor mass. More importantly, TCP-1/TNFα attenu-
ated the immunosuppressing effects of TNFα in bone 
marrow and spleen with marked reduction in systemic 
toxicity [18]. These findings provide a solid proof that 
TCP-1/TNFα could be used to treat CRC through syner-
gistic effects with standard chemotherapeutic agents as 
targeted therapy.
Interferon gamma (IFNγ) is a pleiotropic cytokine pro-
duced by immune cells and plays physiologically impor-
tant roles in promoting innate and adaptive immune 
responses [18, 19]. It is also indicated that IFNγ could 
induce the antiproliferative and proapoptotic effects on 
various tumor cells, repress tumor angiogenesis and pro-
duce antitumor cellular responses through activation of 
natural killer cells, macrophages and CD8+ cytotoxic T 
cells [20]. But similar to TNFα, IFNγ lacks a unique selec-
tivity as an antitumor agent and can bind to most of cells 
due to ubiquitous expression of its receptor [21]. There-
fore, IFNγ failed in several clinical trials as a sole antitu-
mor agent due to low maximal tolerated dose in patients 
[19, 21]. Tumor vasculature targeting approach also has 
been used to deliver IFNγ to tumor tissues for targeted 
therapy. Several studies of targeted IFNγ have obtained 
promising results [21–23]. Low dose of targeted IFNγ 
can produce significant tumor growth inhibition in dif-
ferent tumor types [22].
TNFα and IFNγ have been shown to have synergis-
tic antitumor effect in a few cell line studies [24–27]. 
Relevant study also demonstrated that co-administra-
tion of targeted TNFα and nontargeted IFNγ resulted 
in significant synergistic tumoricidal activity in renal 
cell carcinoma. However, early clinical studies failed in 
patients with advanced gastrointestinal cancers through 
co-administration of non-targeted TNFα and IFNγ [28–
31]. Targeted delivery of TNFα or IFNγ not only reduces 
the effective dose of individual cytokines and enhances 
their local concentration in tumors, but also enlarges 
their therapeutic window. More importantly it is likely 
that the combination of targeted TNFα and IFNγ might 
produce more effective antitumor activity than either 
agent given alone. This could further reduce the dosage 
of each agent, which will markedly reduce the potential 
side effects produced by these agents and make the treat-
ment more viable in cancer patients. Here, we explored 
the antitumor effect of targeted TNFα or IFNγ in CRC 
through using fusion protein of TNFα or IFNγ with 
TCP-1 peptide, a novel ligand which can specifically bind 
to the vasculature of orthotopic colorectal tumors [24–
27]. Furthermore, the antitumor activity and mechanism 




The murine CRC cell Colon 26 was obtained from the 
Health Science Research Resources Bank (Osaka, Japan). 
Mouse fibroblast cell line L929 for IFNγ activity determi-
nation was purchased from the Shanghai Cell Bank of the 
Chinese Academy of Sciences (Shanghai, China). Cells 
were grown in RPMI 1640 supplemented with 100  U/
mL penicillin G, 100 μg/mL streptomycin, and 10 % fetal 
bovine serum (FBS) and maintained at 37 °C in a humidi-
fied atmosphere containing 5 % CO2. Male BALB/c mice 
aged 6  weeks were maintained at the Chinese Univer-
sity of Hong Kong Animal Facility. Animal experiments 
in this project had been approved by the Laboratory 
Animals Ethics Committee of the Chinese University of 
Hong Kong.
Reagents and antibodies
Anti-mouse CD31 (553274), anti-mouse CD4 (553043) 
and anti-mouse CD8 (550281) monoclonal antibodies 
were purchased from BD Pharmingen. Anti-caspase-3 
(9662), anti-PARP (9542), anti-β-actin (4967) antibod-
ies were obtained from Cell Signaling Technology. 
PE-Cy™ 7 anti-mouse CD3 (100320), PE anti-mouse CD4 
(103405) and FITC anti-mouse CD8a (100706), APC 
anti-mouse CD34 (128612), PE-Cy™ 7 anti-mouse CD45 
(103222) antibodies, and isotype IgG were purchased 
from Biolegend. In Situ Cell Death Detection Kit (Fluo-
rescein) was brought from Roche. Dead Cell Apoptosis 
Kit with Annexin V FITC and PI was purchased from 
ThermoFisher.
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Orthotopic CRC model
Animals were anesthetized with a mixture of ketamine 
and xylazine. A 29-gauge syringe was used to inject 
2.5 ×  104 colon 26 cells, suspended in RPMI 1640 with 
10 % FBS, submucosally into the distal, posterior rectum. 
The injection was performed approximately 1–2  mm 
beyond the anal canal and into the rectal mucosa, which 
minimized the chance of establishing anal tumors. 
Tumors were developed at 1.5–2 weeks. Successful mod-
els were used for various in vivo anti-cancer experiments 
after tumors were formed.
Plasmid construction
The IFNγ and TCP-1/IFNγ plasmids were constructed 
using method similar to that previously described for 
TNFα and TCP-1/TNFα [18]. The mouse IFNγ frag-
ment was amplified by PCR from mouse spleen cDNA 
with primer pair 5′-CAT GGT ACC CAC GGC ACA 
GTC ATT GAA AGC CTA-3′and 5′-CAT GGA TCC 
TCA GCA GCG ACT CCT TTT CCG CTT C-3′ flanked 
by KpnI and BamHI restriction enzyme sites. The PCR 
product was then cloned into a modified pET-14b vector. 
Subsequently, the TCP-1 gene was introduced into con-
structed pET-14b/IFNγ plasmid by PCR-mediated site-
directed mutagenesis with the primer pair 5′-TTT TCG 
CAT TGC GGA GGT ACC CAC GGC ACA GTC ATT 
GAA AGC CTA-3′ and 5′-AGG ACT AGG CGT ACA 
AGC GGG CCC CAT ATG GCT GCC GCG CGG-3′. All 
the constructs were finally confirmed by DNA sequenc-
ing. The flow chart of plasmid construction is shown in 
Additional file 1: Fig. S1.
Protein expression, purification and verification
The protein expression and purification procedure was 
performed as previously described [18]. Proteins with 
>90  % purity based on SDS-PAGE image were used for 
various examinations. The quantitative chromogenic 
Limulus amebocyte lysate (LAL) test was used to quan-
titate Gram-negative bacterial endotoxin. The endotoxin 
concentration in the purified proteins used in the study is 
approximately 0.1 EU/μg.
IFNγ activity assay
The activities of IFNγ and TCP-1/IFNγ were determined 
in L929 and Colon 26 cells by MTT assay. Briefly, 2 × 103 
cells/well were seeded in a 96-well plate with 100  μL 
growth medium. After 24  h, different concentrations of 
IFNγ and TCP-1/IFNγ were added for an additional 72 h. 
Subsequently, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphe-
nyltetrazolium bromide (MTT) was used to detect the 
cell viability.
Animal treatment
To investigate whether TCP-1 peptide is able to deliver 
IFNγ to tumor blood vessels, 50 nmol TCP-1/IFNγ fusion 
protein or equal molar IFNγ was i.v. injected through tail 
vein into mice bearing orthotopic CRC to examine the 
distribution of IFNγ. The proteins were allowed to circu-
late for 1 h. Tumor and control tissues were collected and 
prepared for frozen section. Blood vessels were stained 
with anti-CD31 antibody. IFNγ signal was amplified by 
biotin-labeled anti-His tag antibody. To study the short-
term effect of IFNγ or TCP-1/IFNγ, 5 μg of IFNγ or equal 
dose of IFNγ in TCP-1/IFNγ, was i.v. injected into mice 
bearing orthotopic CRC. Animals were sacrificed 24  h 
after injection. For antitumor experiment, mice bearing 
orthotopic CRC were randomized into different group 
(n  ≥  4): PBS, TNFα (1  μg/mouse), TCP-1/TNFα (1  μg 
TNFα/mouse), IFNγ (5  μg/mouse), TCP-1/IFNγ (5  μg 
IFNγ/mouse), TNFα (0.5  μg/mouse) plus IFNγ (2.5  μg/
mouse) and TCP-1/TNFα (0.5 TNFα μg/mouse) plus 
TCP-1/IFNγ (2.5 μg IFNγ/mouse). Treatment was given 
by i.v. injection again through tail vein once. Mice were 
euthanized at 7  days after drug administration. Tumors 
and control organs were dissected and prepared for fro-
zen sections. Tumor microvessel density and apoptosis 
were assessed.
Histology
At the end of experiment, mice were heart-perfused with 
4 % neutral-buffered paraformaldehyde and tumors were 
obtained for frozen section. Frozen sections were pro-
cessed and immunofluorescent and immunohistochemi-
cal staining were performed as previously described [18].
Western blots and flow cytometry
Western blots and flow cytometry were performed fol-
lowing the standard laboratory protocol as previously 
reported [18].
Hochest and PI double staining
Frozen tissue sections were washed in PBS and double-
stained with propidium iodide (PI, 2.5 mg/mL) and Hoe-
chst 33342 (2.5  mg/mL) for 10  min. Intact blue nuclei, 
condensed/fragmented blue nuclei, condensed/frag-
mented pink nuclei, and intact pink nuclei were consid-
ered viable, early apoptotic, late apoptotic and necrotic 
cells, respectively.
Statistical analysis
The results are expressed as mean  ±  SEM. GraphPad 
Prism 5 (GraphPad Software) was used for statistical 
analysis. Two tailed Student’s t test was applied for paired 
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data analysis. For the in vivo treatment experiment with 
TCP-1 fusion proteins, comparisons among all groups 
were analyzed by one-way ANOVA followed by the Tuk-
ey’s test. P value below 0.05 was considered statistically 
significant.
Results
Targeted delivery of IFNγ by TCP‑1 in the orthotopic CRC 
model
IFNγ and TCP-1/IFNγ plasmids were constructed by 
similar procedures with that of TNFα and TCP-1/TNFα 
(Fig.  1a; Additional file  1: Fig. S1). The respective pro-
teins were expressed in E. coli and purified by Ni–NTA. 
Reducing SDS-PAGE of TNFα and TCP-1/TNFα mainly 
showed a single band of around 20  kD (TNFα, 20  kD; 
TCP-1/TNFα, 22 kD). Consistent with the fact that IFNγ 
could form a homodimer, reducing SDS-PAGE of IFNγ 
and TCP-1/IFNγ mainly showed a single band of around 
13  kD (IFNγ, 13  kD; TCP-1/IFNγ, 15  kD), which was 
expected for monomeric IFNγ (Fig.  1b), whereas non-
reducing SDS-PAGE of these two proteins showed two 
bands of around 13, 26 kD, corresponding to monomers 
and dimmers respectively (data not shown). The cyto-
static activities of IFNγ and TCP-1/IFNγ were deter-
mined in a murine fibrosarcoma cell line (L929) and a 
mouse colonic adenocarcinoma cell line (Colon 26). The 
effect of TCP-1/IFNγ had no obvious difference from 
that of IFNγ as determined by the standard cytotoxicity 
assay (Fig. 1c). Fusion of IFNγ with TCP-1 did not affect 
the cytotoxicity of IFNγ on these cell lines. These find-
ings indicated that TCP-1 peptide did not change IFNγ 
folding, oligomerization, activity and binding to IFNγ 
Fig. 1 Purification, targeted delivery and functional characterization of IFNγ and TCP-1/IFNγ. a Schematic representation of TCP-1/IFNγ and IFNγ 
fusion proteins. The TCP-1 peptide was fused to N-terminal of IFNγ protein. b Purification of TNFα, TCP-1/TNFα, IFNγ and TCP-1/IFNγ. Recombinant 
proteins were purified using Ni–NTA resin followed by SDS-PAGE and coomassie blue staining. c Activity analysis of IFNγ and TCP-1/IFNγ on L929 
and Colon 26 cells. Cell viability was determined by MTT assay. d 50 nmol IFNγ or TCP-1/IFNγ was i.v. injected into tumor-bearing mice. Mice were 
sacrificed 1 h later and localization of IFNγ or TCP-1/IFNγ was detected by anti-His tag antibody (green). White arrows indicate areas where TCP-1/
IFNγ was colocalized with CD31 (red) in the tumor blood vessels. IFNγ alone did not bind to the blood vessels of tumor tissues. e Immunohisto-
chemistry of MHC-I (H-2Kb). 5 μg IFNγ or TCP-1/IFNγ was i.v. injected into tumor-bearing mice. Mice were sacrificed 24 h later. f 5 μg IFNγ or TCP-1/
IFNγ was i.v. injected into tumor-bearing mice. Mice were sacrificed 1 h later. Apoptotic cells (green) in tumor mass were detected by TUNEL assay. 
TCP-1/IFNγ could obviously induce more apoptosis of tumor cells when compared with the non-targeted IFNγ
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receptors, thereby producing equipotent cytotoxicity 
on cells. To directly test whether TCP-1 peptide could 
deliver IFNγ to tumor vasculature, we injected 50 nmol 
IFNγ or TCP-1/IFNγ into mice bearing orthotopic CRC 
through tail veins. Data showed that TCP-1/IFNγ could 
colocalize with tumor vasculature (Fig. 1d), but not with 
blood vessels in normal organs including brain, heart and 
normal colon tissues (Additional file 2: Fig. S2), indicat-
ing that IFNγ protein did not negatively affect the bind-
ing ability of TCP-1 to tumor vasculature. It has been well 
reported that IFNγ could up-regulate MHC-I expression 
[32]. Therefore, the effect of IFNγ and TCP-1/IFNγ on 
MHC-I expression was determined in  vivo. After 24  h 
treatment, TCP-1/IFNγ induced more MHC-I expression 
inside the tumor than control or IFNγ (Fig. 1e), indicat-
ing more IFNγ was accumulated in the tumor by targeted 
delivery by TCP-1 peptide. We next briefly investigated 
the therapeutic effect of TCP-1/IFNγ in  vivo. Results 
showed that TCP-1/IFNγ given 24 h induced more apop-
tosis when compared to the control and IFNγ groups 
(Fig. 1f ).
TCP‑1/TNFα or TCP‑1/IFNγ given alone inhibited orthotopic 
colorectal tumor growth
We next determined the in  vivo antitumor activity of 
TCP-1/TNFα and TCP-1/IFNγ (Fig.  2a). We used the 
dose of 1  μg/mouse for TNFα and TCP-1/TNFα and 
5 μg/mouse for IFNγ and TCP-1/IFNγ according to pre-
vious experiment which indicated that 5 μg TCP-1/IFNγ 
can induce maximal anti-tumor effect (Additional file 3: 
Fig. S3) [18]. Compared with the control group, TNFα 
or IFNγ slightly but not significantly suppressed tumor 
growth, while TCP-1/TNFα or TCP-1/IFNγ significantly 
decreased tumor size compared with their unconjugated 
counterparts (Fig. 2b–d). This suggests that conjugation 
with TCP-1 peptide magnified the antitumor activity of 
TNFα and IFNγ. For all proteins, there were no myelo-
suppression observed at indicated dosage as reflected 
by similar levels of CD34bright CD45dim hematopoietic 
cells in the bone marrow (Fig.  2e). To further elucidate 
the antitumor action of TCP-1/TNFα and TCP-1/IFNγ, 
the level of apoptosis was examined. Concordantly, both 
TUNEL staining (Fig. 2f ) and immunofluorescence stain-
ing for cleaved caspase-3 (Fig. 2g) revealed that TNFα or 
IFNγ increased the number of apoptotic cells inside the 
tumor while conjugation with TCP-1 further induced 
apoptosis. Proteins given at the indicated doses did not 
cause significant vessel destruction (Fig. 2h).
TCP‑1/TNFα combined with TCP‑1/IFNγ dramatically 
inhibited orthotopic colorectal tumor growth
To determine the combined effect of TCP-1/TNFα 
and TCP-1/IFNγ on tumor growth, mice were divided 
into three groups: control (PBS), TNFα (0.5  μg/mouse) 
combined with IFNγ (2.5  μg/mouse) and TCP-1/TNFα 
(0.5  μg/mouse) combined with TCP-1/IFNγ (2.5  μg/
mouse). Due to systemic toxicity, mice given TNFα 
combined with IFNγ all died within 2  days while the 
group given the same dose but conjugated with TCP-1 
all survived (Fig.  3a). The data demonstrated that tar-
geted delivery of TNFα combined with IFNγ by TCP-1 
peptide drastically inhibited tumor growth than single 
treatment (Fig. 3b–d; Additional file 4: Fig. S4A, B) and 
at the same time alleviated systematic toxicity induced 
by non-targeted TNFα and IFNγ. More importantly, 
TCP-1/TNFα combined with TCP-1/IFNγ did not 
reduce CD34bright CD45dim hematopoietic cells in the 
bone marrow (Fig.  3e), suggesting no myelosuppression 
was caused. Although there was a little body weight drop 
at 2  days after treatment (Additional file  4: Fig. S4C), it 
gradually caught up and there was no obvious toxicity 
observed in normal organs including colon, liver, kid-
ney, etc. (Additional file 4: Fig. S4D). TCP-1/TNFα com-
bined with TCP-1/IFNγ induced massive cell death in the 
tumor (>90 %) as shown by the TUNEL staining (Fig. 3f ) 
and also cell death of the tumor vasculature (Fig.  3g). 
Our results indicated that targeted delivery of these two 
cytokines by TCP-1 peptide holds great promise for colo-
rectal cancer therapy.
TCP‑1/TNFα and TCP‑1/IFNγ enhanced antitumor immunity
To investigate the immunotherapeutic responses, 
immune cell infiltration in the tumor was determined. 
Immunofluorescence staining showed that TNFα 
increased both CD8+ cytotoxic and CD4+ helper T lym-
phocytes inside the tumor while IFNγ increased CD4+ T 
cell. Compared with the unconjugated TNFα and IFNγ, 
the conjugated groups through TCP-1 further increased 
the infiltration of both CD8+ and CD4+ T cell in the 
tumor (Fig. 4a, b). However, there was no T lymphocyte 
infiltration observed in the TCP-1/TNFα and TCP-1/
IFNγ combined group, suggesting the combined treat-
ment group may not exert its antitumor effect through 
enhancing immune surveillance. The above result was 
further confirmed by flow cytometry (Fig.  4c). Both 
TCP-1/TNFα and TCP-1/IFNγ increased CD3+ cells in 
the spleen meaning more T lymphocytes were generated 
by the spleen. On the other hand, the peripheral blood 
cell analysis disclosed that there were more CD3+ cells in 
the peripheral blood for the TNFα treated group, indicat-
ing that fewer T lymphocytes has entered the tumor for 
this group. All other groups showed similar population 
of CD3+ cells in the peripheral blood compared with the 
control group. We have also determined the number of 
macrophages, NK cells, B cells and granulocytes inside 
the tumor, however, no obvious change was observed for 
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all treatment groups (Additional file  5: Fig. S5). Taken 
together, the data suggest that TCP-1/TNFα and TCP-1/
IFNγ could increase the generation of T lymphocyte in 
the spleen and enhance the penetration of T lymphocytes 
into the tumor. The TCP-1/TNFα and TCP-1/IFNγ com-
bined treatment group inhibited tumor growth by dif-
ferent mechanisms from targeted TNFα or IFNγ alone 
which is highly associated with antitumor immunity.
Mechanism of action of TCP‑1/TNFα combined with TCP‑1/
IFNγ
To elucidate the mechanism by which TCP-1/TNFα 
combined with TCP-1/IFNγ induced massive cell death 
inside the tumor, Hochest and PI double stain was first 
performed in frozen tissue sections. PI is only permeant 
to dead cells. As shown in Fig.  5a, cells in the control 
tumor were not permeable to PI while cells in the com-
bined treatment group were permeable to PI and had 
condensed (pyknosis) and fragmented nucleus (karyor-
rhexis) suggesting the cells were undergoing late apopto-
sis or necrosis. The morphology of the nucleaus was more 
clearly shown by H & E staining (Fig. 5b). Next, expres-
sion of apoptosis markers cleaved caspase-3 and PARP in 
the tumor were determined. Results showed that TCP-1/
TNFα or TCP-1/IFNγ increased cleavage of caspase-3 
and PARP while such effect was not found in the TCP-1/
TNFα and TCP-1/IFNγ combined treatment group 
(Fig. 5c). On the contrary, there was a little reduction in 
the expression of total caspase-3, total PARP and cleaved 
PARP proteins. We hypothesized that the cells were at 
late stage of cell death and that the proteins in the cells 
were being degraded. To further clarify how the cells in 
the tumor died after TCP-1/TNFα and TCP-1/IFNγ com-
bined treatment, we used the colon 26 cells to determine 
the effect of TNFα combined with IFNγ in vitro. We used 
the same ratio of TNFα to IFNγ as that of in vivo study 
(1:5). TNFα (100  ng/mL) and IFNγ (500  ng/mL) syner-
gistically inhibited cell growth as shown by MTT assay 
(Fig. 5d). LDH assay is to detect plasma membrane dam-
age which is a hallmark of late apoptosis/necrosis in vitro. 
Result of this assay showed that TNFα plus IFNγ induced 
plasma membrane damage to a great extent (Fig.  5d). 
Western blot result showed that combined treatment 
by TNFα and IFNγ induced caspase-3 and PARP cleav-
age which was earlier than either cytokine alone (Fig. 5e). 
Using flow cytometry of Annexn V and PI, we found that 
combined treatment by TNFα and IFNγ induced drastic 
cell death (late apoptosis or necrosis) at 48  h while the 
effect of both cytokines alone was minimal (Fig. 5f ). Time 
course study showed that the cells went through early 
apoptosis to cell death (Fig. 5g). Moreover, the possibil-
ity of other cell death pathways including autophagy and 
senescence were excluded (Additional file 6: Fig. S6). Col-
lectively, we conclude that the cells died by going through 
apoptosis not primary necrosis.
Discussion
Tumor vasculature undergoing angiogenesis expresses 
specific endothelial surface markers which are absent 
or barely detectable in mature vessels [33]. Peptide has 
many advantages over antibody as drug carrier [34]. 
Therefore, tumor-homing peptides (THPs) that target 
tumor vasculature are important and promising imaging 
agent and drug delivery vectors [35]. Using phage display 
biopanning, we previously identified a novel cyclic pep-
tide TCP-1 which can specifically bind to the vasculature 
of colorectal tumor in both animals and humans but not 
normal blood vessels. We have also shown that TCP-1 
is useful for targeted delivery of imaging agent and pro-
apoptotic peptide [17]. This peptide is advantageous over 
other THPs because it exhibits a unique homing ability to 
the vasculature only in the CRC, indicating its specific-
ity and accuracy as a carrier in CRC diagnosis and ther-
apy. The TNFα and IFNγ synergism has been reported 
under many biological conditions including their tumor 
inhibitory effect [25, 26, 36–38]. Early clinical trials con-
ducted in 1990s tried to use the combination of these 
two cytokines to treat advanced gastrointestinal cancer 
patients [27–30]. Unfortunately only modest beneficial 
effects but severe side effects were seen. In  vivo study 
showed that combination of nontargeted TNFα and IFNγ 
often show significant toxicity [39]. Targeted TNFα and 
nontargeted IFNγ exerted additive tumoricial activity in 
renal cell carcinoma [25]. However, direct proof of the 
(See figure on previous page.) 
Fig. 2 Antitumor activity of TNFα, TCP-1/TNFα, IFNγ or TCP-1/IFNγ single treatment in the orthotopic CRC model. a Schematic representation of 
treatment regimen in the orthotopic CRC model. b Representative picture of the tumors in all groups after treatment for 7 days (n ≥ 4 per group). 
c Tumor weight at sacrifice and d Tumor size along with time in all treatment groups. Tumor size of each mouse was normalized to that measured 
at beginning of treatment. TCP-1/TNFα and TCP-1/IFNγ significantly inhibited tumor growth compared with the control group and their respective 
unconjugated proteins. e CD34bright CD45dim hematopoietic cells in bone marrow. There was no myelosuppression in all treatment groups. f Apop-
tosis in tumor mass was detected by TUNEL assay and quantified. There were more TUNEL positive cells in the TNFα and TCP-1/TNFα treated groups 
compared with the control group. g Immunofluorescence staining for cleaved caspase-3 and quantification result. Compared with the control 
group, TNFα and IFNγ groups showed a little but not significant increase in cleaved caspase-3 while TCP-1/TNFα and TCP-1/IFNγ groups significantly 
increased cleaved caspase-3. h Immunohistochemistry staining for CD31 showing the effect of treatment on tumor blood vessel. There was no 
obvious vessel destruction for all treatment groups. Data were presented as mean ± SEM. *P < 0.05. **P < 0.01. ***P < 0.001
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Fig. 3 Antitumor activity of TCP-1/TNFα in combination with TCP-1/IFNγ in the orthotopic CRC model. a Survival comparison between nontar-
geted and targeted TNFα and IFNγ combined treatment groups. TCP-1/TNFα and TCP-1/IFNγ combination group significantly improved survival 
compared with the nontargeted TNFα and IFNγ group. b Representative picture of the tumors in control and combined groups after treatment for 
7 days (n ≥ 4 per group). TCP-1/TNFα and TCP-1/IFNγ combination treatment dramatically inhibited tumor growth. c Tumor weight at sacrifice and 
d Tumor size along with time in all treatment groups (n ≥ 4 per group). e CD34bright CD45dim hematopoietic cells in bone marrow. No myelosup-
pression was observed for TCP-1/TNFα in combination with TCP-1/IFNγ. f Representative picture of TUNEL staining and quantification. Combination 
treatment increased TUNEL positive cells inside the tumor. g Representative picture of CD31 immunohistochemistry staining and quantification. 
TCP-1/TNFα in combination with TCP-1/IFNγ decreased tumor blood vessel. Data were presented as mean ± SEM. **P < 0.01. ***P < 0.001
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antitumor effect of targeted TNFα combined with tar-
geted IFNγ in vivo has not been reported before.
In this study, we extended to study the effect of TCP-1/
TNFα and TCP-1/IFNγ either alone or in combination 
in orthotopic colorectal tumor model in immune-com-
petent mice. We found that TNFα (1 μg/mouse) or IFNγ 
(5  μg/mouse) slightly increased tumor apoptosis while 
conjugation with TCP-1 peptide significantly inhibited 
tumor growth and increased tumor cell apoptosis. TNFα 
exerts different actions in cancer therapy depending on 
the dosage used [40]. High dose of TNFα mainly inhibits 
tumor angiogenesis, leading to vessel destruction which 
decreases the blood flow and oxygen required for the 
progression of tumor growth. Low dose of TNFα could 
induce vessel remodeling and increase vessel perfusion, 
thereby enhancing drug accumulation in the tumor. Our 
previous study has demonstrated that low dose TCP-1/
TNFα could normalize tumor blood vessel, enhance the 
intratumoral accumulation of anticancer drug 5-FU, 











Fig. 4 TNFα, TCP-1/TNFα, IFNγ or TCP-1/IFNγ single treatment enhanced antitumor immunity. a Immunofluorescence staining of CD8+ and CD4+ 
cells in the tumor mass. b Quantification of CD8+ and CD4+ cells in the tumor mass. TCP-1/TNFα and TCP-1/IFNγ single treatment significantly 
increased CD8+ and CD4+ cell infiltration into the tumor. c CD3+ cells in the spleen and peripheral blood detected by flow cytometry. TCP-1/TNFα 
and TCP-1/IFNγ single treatment increased CD3+ cells production in the spleen while decreased or didn’t change its level in peripheral blood, sug-
gesting the treatments increased CD3+ cells at tumor site. Data were presented as mean ± SEM. *P < 0.05. **P < 0.01. ***P < 0.001
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present study, there was no significantly vessel destruc-
tion observed for TNFα or TCP-1/TNFα. Our previous 
result demonstrated that TNFα or TCP-1/TNFα at 5 μg/
mouse could lead to acute vessel destruction. We here 
chose 1  μg/mouse for TNFα which could partly inhibit 
tumor growth and avoid masking the action of combined 
treatment of TCP-1/TNFα and TCP-1/IFNγ. This dos-
age may not be sufficient to induce vessel destruction. 
For IFNγ, consistent with previous findings that a dose–
response curve of IFNγ-NGR is bell-shaped [23], our 
result also showed that TCP-1/IFNγ achieved optimal 
antitumor effect at the dose of 5 μg/mouse. Elevating the 
dose did not ensure better response. In addition to induc-
ing tumor apoptosis, TCP-1/TNFα or TCP-1/IFNγ also 
increased the infiltration of CD8+ and CD4+ T cell in the 
tumor leading to enhanced antitumor immunity. Previ-
ous study has shown that the antitumor effect of targeted 
IFNγ in animal study mainly involves inhibition of angio-
genesis and induction of apoptosis but not infiltration of 
immune cells [22, 40], which is different from our result. 
This difference may be due to the different dose, treat-
ment time and animal model.
Most interestingly, combination treatment by TCP-1/
TNFα and TCP-1/IFNγ dramatically inhibited tumor 
growth. At the beginning we used TCP-1/TNFα (1  μg/
mouse) combined with TCP-1/IFNγ (5  μg/mouse). The 
antitumor effect was very drastic, however a little myelo-
suppression was observed (data not shown). After that, 
we used half the dose: TCP-1/TNFα (0.5  μg/mouse) 
combined with TCP-1/IFNγ (2.5 μg/mouse). The inhibi-
tory effect of combination treatment on tumor growth 
was dose-dependent (data not shown) and no myelo-
suppression or toxicity to other organs was observed for 
the latter combination. TCP-1/TNFα and TCP-1/IFNγ 
combined treatment also significantly improved maxi-
mum tolerance of two cytokines related to side effects 
compared with untargeted TNFα combined with IFNγ 
indicating alleviation of systematic toxicity. Morphologi-
cally, condensed and fragmented nucleus (pyknosis and 
karyorrhexis) were found in high percentage (>90  %) 
inside the tumor treated by combined treatment which 
might be due to late apoptosis or necrosis. Mechanism 
study using mouse colon cancer cells, colon 26 cells 
reveals that the cells treated with TNFα and IFNγ pass 
through early apoptosis to late apoptosis/secondary 
necrosis but not through primary necrosis.
Although we have shown that combined treatment of 
TCP-1/TNFα and TCP-1/IFNγ induced late apoptosis/
secondary necrosis, the molecular mechanism remains 
elusive. According to previous studies, TNFα induced 
NF-κB signaling could counteract TNFα-induced apop-
tosis [41, 42] while IFNγ could inhibit NF-κB activation 
and the expression of downstream apoptosis inhibitors, 
finally sensitizing the cancer cells to TNFα treatment 
[24, 26]. However, our results showed that the expres-
sion of apoptosis inhibitor downstream of NF-κB includ-
ing XIAP and c-IAP-1 were not changed by either TNFα 
or combined treatment (Additional file 6: Fig. S6). It has 
also been proposed that TNFα and IFNγ synergistically 
inhibit cancer cell growth because IFNγ increases the 
expression of TNFα receptors [43, 44]. However, it is also 
argued that increase of TNFα receptors is not the major 
mechanism underlying the synergism between TNFα and 
IFNγ. STAT1/IRF-1 pathways initiated by IFNγ had been 
shown to be important in TNFα and IFNγ synergism in 
inducing cervical cancer cell apoptosis [26]. However, 
neither STAT1 nor IRF-1 could totally explain the prim-
ing effect of IFNγ in TNFα-indiced apoptosis. It seems 
that the TNFα and IFNγ synergism requires multiple 
factors, and research evidence so far has not pointed to 
a conclusion. Further studies are warranted to delineate 
the potential molecular mechanism.
Conclusions
Our results demonstrate for the first time that TCP-1/
TNFα and TCP-1/IFNγ combination is very promising as 
potential CRC therapy. The synergistic antitumor activ-
ity of TNFα combined with IFNγ has been exploited in 
(See figure on previous page.) 
Fig. 5 TCP-1/TNFα combined with TCP-1/IFNγ induced late apoptosis/secondary necrosis. a Hochest and PI double staining of tumor frozen sec-
tions from control and TCP-1/TNFα and TCP-1/IFNγ combined treatment groups. PI is only permeant to dead cells. PI positive staining was found 
in tumor cells in the TCP-1/TNFα and TCP-1/IFNγ combination treatment group but not control group indicating combination treatment induced 
late apoptosis/secondary necrosis. b H & E staining of tumor frozen sections. The combination treatment group had condensed (pyknosis) and 
fragmented nucleus (karyorrhexis) suggesting the cells were undergoing late apoptosis or necrosis. c Western blot result of cleaved caspase-3 and 
cleaved PARP in the tumors. Semi-quantification of cleaved caspase-3 and PARP is done using ImageJ software. TCP-1/TNFα and TCP-1/IFNγ single 
treatment induced apoptosis as shown by induction of cleaved caspase-3 and PARP while the combined treatment group did not show such effect. 
d MTT and LDH assay of colon 26 cells treated by PBS, TNFα, IFNγ or TNFα plus IFNγ. Ratio of TNFα to IFNγ was determined according to in vivo study. 
TNFα and IFNγ synergistically inhibited colon 26 cell growth and caused membrane damage at 48 h. e Western blot result of cleaved caspase-3 and 
cleaved PARP in colon 26 cells treated for different time. Semi-quantification of cleaved caspase-3 and PARP is done using ImageJ software. TNFα 
plus IFNγ induced apoptosis earlier than TNFα or IFNγ alone. f Flow cytometry result of Annexin V and PI double staining. TNFα plus IFNγ induced 
massive late apoptosis/necrosis at 48 h. g Time course study was performed with TNFα plus IFNγ at different time points. Results demonstrated that 
this cell death was through early apoptosis to late apoptosis/necrosis. C control, T TNFα, I IFNγ, TT TCP-1/TNFα, TI TCP-1/IFNγ. Data were presented as 
mean ± SEM. *P < 0.05. ***P < 0.001
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early clinical trials, but the result was disappointing due 
to systematic toxicity and limited beneficial effect. Our 
study could overcome this drawback by enhancing the 
anticancer action of TNFα combining with IFNγ so that 
lower doses of both cytokines can be given to patients 
to achieve promising outcome with less systemic side 
effects. Since both cytokines are being used in human to 
treat different diseases, the approach suggested from the 
current study would provide the likelihood of using drug 
combination of TCP-1/TNFα and TCP-1/IFNγ for future 
clinical trials to treat CRC.
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